Larvol Delta - AltruBio-Announces-FDA-Clearance-of-IND-Application-for-ALTB268-a-NextGeneration-Immune-Checkpoint-Enhancer-for-the-Treatment-of-Ulcerative-Colitis

leiolizumab (ALTB-268) - AltruBio

https://www.globenewswire.com/news-release/2022/12/06/2568234/0/en/AltruBio-Announces-FDA-Clearance-of-IND-Application-for-ALTB-268-a-Next-Generation-Immune-Checkpoint-Enhancer-for-the-Treatment-of-Ulcerative-Colitis.html

Dec 6, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next